Displaying drugs 126 - 150 of 792 in total
Rimegepant
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974 ... ] and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Bulevirtide
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility ... and Orphan Drug Designation by the European Medicines Agency. ... of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ferric derisomaltose
Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020 ... This drug is a complex of iron (III) hydroxide and derisomaltose. ... Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. …
Octreotide
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is...
Approved
Investigational
Matched Description: … On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA ... Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also ... , including carcinoid tumors and vasoactive intestinal tumors (VIPomas). …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatostatin and Analogues …
Matched Products: … SANDOSTATIN LAR 20 MG. ... SANDOSTATIN LAR FOR INJECTION 20 mg ... SANDOSTATIN LAR 20 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatostatin and Analogues …
Matched Products: … SANDOSTATIN LAR 20 MG. ... SANDOSTATIN LAR FOR INJECTION 20 mg ... SANDOSTATIN LAR 20 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET …
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Description: … An antiandrogen with about the same potency as cyproterone in rodent and canine species. …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Elapegademase
Elapegademase is a PEGylated recombinant adenosine deaminase. It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues. Elapegademase is generated in E. coli,...
Approved
Matched Synonyms: … PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED ON N.ALPHA..1ALANINE AND ... 356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND …
Matched Description: … as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and ... [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on ... with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Description: … as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and ... [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on ... with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Azithromycin
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for...
Approved
Matched Description: … In March 2020, a small study was funded by the French government to investigate the treatment of COVID ... It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be ... used instead of other macrolides for some sexually transmitted and enteric infections. …
Matched Categories: … cefixime and azithromycin ... azithromycin, fluconazole and secnidazole ... Macrolides, Lincosamides and Streptogramins …
Matched Categories: … cefixime and azithromycin ... azithromycin, fluconazole and secnidazole ... Macrolides, Lincosamides and Streptogramins …
Azacitidine
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it...
Approved
Investigational
Matched Description: … azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020 ... As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and ... inhibiting protein and DNA synthesis. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Description: … [A254172]
In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. ... HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide ... Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Crizanlizumab
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020 ... It was developed by Novartis and was granted FDA approval on November 15, 2019. ... L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Brexucabtagene autoleucel
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under ... ], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy ... Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Atoltivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. ... neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against ... attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Maftivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. ... neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against ... attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers ... indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. ... ] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of ... in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761]
Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Gallium Ga-68 gozetotide
Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries...
Approved
Matched Description: … [L27006]
On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted ... L26981] Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries and ... prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and …
Matched Categories: … Indicators and Reagents …
Matched Categories: … Indicators and Reagents …
Mucor circinelloides f. circinelloides
Mucor circinelloides f. circinelloides allergenic extract is used in allergenic testing.
Approved
Matched Synonyms: … Molds, rusts and smuts, mucor circinelloides f. circinelloides …
Fidaxomicin
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is...
Approved
Matched Description: … [A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric ... bactericidal activity is time-dependent, and not concentration-dependent. ... the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and …
Matched Categories: … Alimentary Tract and Metabolism …
Matched Products: … DİFİCLİR 200 MG FİLM KAPLI TABLET, 20 ADET …
Matched Categories: … Alimentary Tract and Metabolism …
Matched Products: … DİFİCLİR 200 MG FİLM KAPLI TABLET, 20 ADET …
Ansuvimab
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … [A207646]
Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga ... to be superior, with improved patient survival and faster viral clearance rates. ... [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Viltolarsen
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … [A218176]
Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing ... [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Elbasvir
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Description: … [A19626]
In a computational target-based drug repurposing investigation published in April 2020, elbasvir ... for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. ... achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% …
Matched Categories: … elbasvir and grazoprevir …
Matched Categories: … elbasvir and grazoprevir …
Ethanol
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Approved
Matched Description: … It has bactericidal activity and is used often as a topical disinfectant. ... A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout ... It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as …
Matched Mixtures name: … Lord and Berry ... Alcohol and Dextrose ... Alcohol and Dextrose …
Matched Categories: … Antiseptics and Disinfectants …
Matched Products: … RX 2020 Hand Sanitizer ... Diarte 20/20 ANTISEPTIC HAND SANITIZER ... Care 2020 Advanced Hand Sanitizer …
Matched Mixtures name: … Lord and Berry ... Alcohol and Dextrose ... Alcohol and Dextrose …
Matched Categories: … Antiseptics and Disinfectants …
Matched Products: … RX 2020 Hand Sanitizer ... Diarte 20/20 ANTISEPTIC HAND SANITIZER ... Care 2020 Advanced Hand Sanitizer …
Moxetumomab pasudotox
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to...
Approved
Investigational
Matched Synonyms: … Moxetumomab pasudotox ... moxetumomab pasudotox-tdfk …
Matched Name: … Moxetumomab pasudotox …
Matched Description: … The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 ... the status of Fast Track, Priority Review and Orphan Drug designations. ... expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and …
Matched Categories: … moxetumomab pasudotox ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Name: … Moxetumomab pasudotox …
Matched Description: … The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 ... the status of Fast Track, Priority Review and Orphan Drug designations. ... expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and …
Matched Categories: … moxetumomab pasudotox ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Name: … Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen …
Matched Description: … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed ... There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated …
Matched Description: … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed ... There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated …
Displaying drugs 126 - 150 of 792 in total